

Abstract from HAEi Global Leadership Workshop, Frankfurt 6–9 Oct 2022

HAE with normal C1 esterase inhibitor (HAEnC1INH): Diagnosis, treatment and attack frequency from the 2020 Canadian patient survey

Jacquie Badiou¹, Michelle Cooper¹, Daphne Dumbrille¹, Robert Bick², Suzanne M. Kelly³, Amin Kanini⁴, Chrystyna Kalicinsky⁵, Gina Lacuesta⁶, William H. Yang⁷

1) Hereditary Angioedema Canada. 2) Health Policy Consultant, Markham, ON, Canada. 3) Red Maple Trials Inc., Ottawa, ON, Canada. 4) University of British Columbia, Vancouver, BC, Canada. 5) University of Manitoba, Winnipeg, MB, Canada. 6) Dalhousie University, Halifax, NS, Canada. 7) Ottawa Allergy Research Corporation, University of Ottawa, Ottawa, ON, Canada

Rationale: There are no diagnostic tests or approved medications for hereditary angioedema with normal C1INH (HAEnC1INH). As a result, diagnosis is difficult and often delayed. The treatments used are the same as for those with HAE with inadequate C1INH.

Methods: An online survey was sent to Canadian HAE patients in 2020 to better understand their health burden and treatments used. We extracted responses from patients who self-reported having HAEnC1INH and analyzed the data to better understand diagnosis, attack frequency and medication use.

Results: HAEnC1INH was self-reported by 45/167 participants (27%). They were mainly female (84%) and 54 (23-91) [mean (range)] years of age. There was a 14-year difference between the age of symptom onset at 26 (1-58) and of diagnosis at 39 (16-68) years of age. In the prior year, 50% of respondents reported having >12 attacks and 43% reported having a laryngeal attack despite 87% of these patients reporting using either prophylactic or on demand medication to treat their HAEnC1INH. Most respondents used pdC1INH to treat acute attacks (IV 30%, SQ 11%) and for prophylaxis IV33%, SQ 24%). Icatibant was used by 30% to treat acute attacks. Access to treatment was provided by a government plan (74%) or by private insurance (21%).

Discussion: There is still a long delay between the onset of symptoms and diagnosis. While most participants have access to treatment, most still have frequent attacks. There is a need for more awareness as well as targeted treatment for those with HAEnC1INH.